Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF V600E -Mutated Anaplastic Thyroid Carcinoma

曲美替尼 达布拉芬尼 医学 内科学 肿瘤科 癌症研究 甲状腺癌 MEK抑制剂 甲状腺间变性癌 威罗菲尼 甲状腺 黑色素瘤 甲状腺癌 MAPK/ERK通路 磷酸化 遗传学 转移性黑色素瘤 生物
作者
Sarah Hamidi,Priyanka Iyer,Ramona Dadu,Maria Gule-Monroe,Anastasios Maniakas,Mark Zafereo,Jennifer Wang,Naifa L. Busaidy,Maria E. Cabanillas
出处
期刊:Thyroid [Mary Ann Liebert, Inc.]
卷期号:34 (3): 336-346 被引量:72
标识
DOI:10.1089/thy.2023.0573
摘要

Background: The dabrafenib plus trametinib combination (DT) has revolutionized the treatment of BRAF V600E -mutated anaplastic thyroid carcinoma (BRAFm-ATC). However, patients eventually develop resistance and progress. Single-agent anti-PD-1 inhibitor spartalizumab has shown a median overall survival (mOS) of 5.9 months. Combination of immunotherapy with BRAF/MEK inhibitors (BRAF/MEKi) seems to improve outcomes compared with BRAF/MEKi alone, although no direct comparison is available. BRAF-targeted therapy before surgery (neoadjuvant approach) has also shown improvement in survival. We studied the efficacy and safety of DT plus pembrolizumab (DTP) compared with current standard-of-care DT alone as an initial treatment, as well as in the neoadjuvant setting. Methods: Retrospective single-center study of patients with BRAFm-ATC treated with first-line BRAF-directed therapy between January 2014 and March 2023. Three groups were evaluated: DT, DTP (pembrolizumab added upfront or at progression), and neoadjuvant (DT before surgery, and pembrolizumab added before or after surgery). The primary endpoint was mOS between DT and DTP. Secondary endpoints included median progression-free survival (mPFS) and response rate with DT versus DTP as initial treatments, and the exploratory endpoint was mOS in the neoadjuvant group. Results: Seventy-one patients were included in the primary analysis: n = 23 in DT and n = 48 in DTP. Baseline demographics were similar between groups, including the presence of metastatic disease at start of treatment ( p = 0.427) and prior treatments with surgery ( p = 0.864) and radiation ( p = 0.678). mOS was significantly longer with DTP (17.0 months [confidence interval CI, 11.9–22.1]) compared with DT alone (9.0 months [CI, 4.5–13.5]), p = 0.037. mPFS was also significantly improved with DTP as the initial treatment (11.0 months [CI, 7.0–15.0]) compared with DT alone (4.0 months [CI, 0.7–7.3]), p = 0.049. Twenty-three patients were in the exploratory neoadjuvant group, where mOS was the longest (63.0 months [CI, 15.5–110.5]). No grade 5 adverse events (AEs) occurred in all three cohorts, and 32.4% had immune-related AEs, most frequently hepatitis and colitis. Conclusions: Our results show that in BRAFm-ATC, addition of pembrolizumab to dabrafenib/trametinib may significantly prolong survival. Surgical resection of the primary tumor after initial BRAF-targeted therapy in selected patients may provide further survival benefit. However, conclusions are limited by the retrospective nature of the study. Additional prospective data are needed to confirm this observation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
乎乎发布了新的文献求助10
1秒前
活泼的大白完成签到,获得积分10
1秒前
花样年华发布了新的文献求助150
2秒前
赘婿的应助被11采纳,获得10
2秒前
孙家贝发布了新的文献求助10
3秒前
3秒前
桐桐的应助被科研小虫采纳,获得10
3秒前
shuyu发布了新的文献求助20
4秒前
4秒前
kay完成签到,获得积分10
4秒前
搜集达人的应助被徐X采纳,获得10
4秒前
5秒前
5秒前
天天快乐的应助被草莓软糖采纳,获得10
6秒前
6秒前
jj发布了新的文献求助10
6秒前
晚晚发布了新的文献求助10
6秒前
outlook发布了新的文献求助10
6秒前
vc的应助被清辉影采纳,获得30
6秒前
王耀田完成签到,获得积分20
7秒前
乐乐的应助被鲁万仇采纳,获得10
7秒前
汉堡包的应助被wbb采纳,获得10
7秒前
xjh的应助被晴天采纳,获得10
7秒前
千空发布了新的文献求助10
7秒前
flora完成签到 ,获得积分20
8秒前
9秒前
Lucas的应助被干就完采纳,获得10
9秒前
坚强孤容发布了新的文献求助10
10秒前
10秒前
11秒前
h哈发布了新的文献求助10
11秒前
11秒前
12秒前
xnz完成签到,获得积分10
12秒前
李楠楠发布了新的文献求助10
12秒前
11发布了新的文献求助10
12秒前
白云猎德完成签到 ,获得积分10
13秒前
14秒前
14秒前
慕青的应助被郑粥粥采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183204
求助须知:如何正确求助?哪些是违规求助? 9572434
关于积分的说明 21825655
捐赠科研通 7779988
什么是DOI,文献DOI怎么找? 3433852
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480148